US Authorizes and Allocates 300,000 Doses of Eli Lilly's COVID-19 Treatment

The U.S. government stated on November 9, 2020, it will allocate 300,000 doses of Eli Lilly's Bamlanivimab to high-risk, COVID-19 patients, with no out-of-pocket costs for the medication.

This action follows the U.S. FDA granted Emergency Use Authorization for Bamlanivimab (LY-CoV555) 700 mg on November 9, 2020. Bamlanivimab is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization.

Lilly stated in a press release it will begin shipping Bamlanivimab immediately to a national distributor, which will distribute it as directed by the U.S. government's allocation program. Weekly allocation decisions will be proportionally based on confirmed COVID-19 cases in each state and territory over the previous seven days, based on data from the U.S. Department of Health and Human Services' Protect data collection platform.